LRP2 (Low-Density Lipoprotein Receptor-Related Protein 2), also known as megalin, is a multi-ligand endocytic receptor belonging to the LDL receptor family. It is predominantly expressed in polarized epithelial cells, particularly in the kidney (proximal tubules), brain (choroid plexus), lungs, and thyroid gland. LRP2 plays critical roles in nutrient uptake, cellular signaling, and metabolic regulation by mediating the endocytosis of diverse ligands, including lipoproteins, vitamins, hormones, and signaling proteins. Its involvement in renal reabsorption of filtered proteins and vitamins (e.g., vitamin D-binding protein) underscores its importance in maintaining systemic homeostasis.
Antibodies targeting LRP2 are essential tools for studying its expression, localization, and function in physiological and pathological contexts. They are widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to investigate LRP2's role in diseases such as diabetic nephropathy, Alzheimer’s disease (via interaction with amyloid-beta), and Dent disease (linked to LRP2 mutations). Commercial LRP2 antibodies are typically raised against specific epitopes, such as extracellular or cytoplasmic domains, and validated for species reactivity (human, mouse, rat). Researchers prioritize antibodies with high specificity and minimal cross-reactivity to ensure accurate detection, given LRP2's structural homology with other LDL receptor family members. Recent studies also explore LRP2's potential as a therapeutic target, further driving demand for reliable antibodies in mechanistic and drug development research.